The INMD Q1 miss was clearly telegraphed by the recent weakness in the stock price. But cutting annual revenue guidance from $495M-$505M to $485M-$495M is hardly a disaster. Stock had already been hit into today's PR, so I think people were expecting a weaker Q1. Plus they have $8.60/share in cash on the balance sheet. I was tempted to grab a few more on the premarket selloff to the $17's. Looks like I should have with the stock rebounding back over $19. I'm trimming some here, but wouldn't be surprised if INMD trades over $20 again soon. One buoyant market right now!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.